Eosinophilic oesophagitis: a novel treatment using Montelukast

Attwood, S.E.A.; Lewis, C.J.; Bronder, C.S.; Morris, C.D.; Armstrong, G.R.; Whittam, J.
February 2003
Gut;Feb2003, Vol. 52 Issue 2, p181
Academic Journal
Background: Eosinophilic oesophagitis is a rarely diagnosed condition involving eosinophil infiltration of the oesophageal mucosa and creating significant symptoms of dysphagia. Failure to diagnose this disorder relates to reluctance to biopsy an apparently normal oesophagus. This is essential for histological diagnosis. To date, treatment success has been achieved only with corticosteroids. We describe here the use of an eosinophil stabilising agent Montelukast for the symptomatic relief of these patients. Patients and methods: Twelve patients have been identified with this condition in our unit since 1995, after thorough investigation of their dysphagia. We commenced eight of these patients on the leukotriene receptor antagonist Montelukast to symptomatically improve their swallowing while avoiding the use of long term corticosteroids. Results: Many of these patients had been previously misdiagnosed, and therefore inappropriately and unsuccessfully treated for an extensive period prior to referral to our unit. All patients were unresponsive to acid suppression therapy alone but showed improvement in their swallowing on Montelukast. Six of eight reported complete subjective improvement, five patients remaining completely asymptomatic on a maintenance regimen. Conclusions: Eosinophilic oesophagitis is a disease that is often misdiagnosed due to lack of awareness and reluctance of clinicians to biopsy an apparently normal oesophagus in dysphagic patients, and therefore obtain a histological diagnosis. Investigation of these patients adds further evidence to this condition being a separate pathological state from gastro-oesophageal reflux and eosinophilic enteritis. Montelukast has been found to be of significant help in the symptomatic control of these patients while avoiding long term corticosteroids use.


Related Articles

  • Proton Pump Inhibitors Therapy for Eosinophilic Esophagitis. Molina-Infante, Javier; Zamorano, Jose; Rivas, Maria D.; Fernandez-Bermejo, Miguel // Journal of Allergy & Therapy;Special2012, Vol. 3 Issue S, Special section p1 

    Proton pump inhibitors (PPIs) are the pharmacological cornerstone for acid-related peptic disorders, especially gastroesophageal reflux disease (GERD), on account of their powerful suppression of gastric acid secretion. GERD is the most common esophageal disease, with approximately 10-20% of...

  • "How I BEAT My Acid-Reflux Nightmare!". Burns, Ralph // Granite City Press-Record;10/12/2011, Vol. 53 Issue 76, pA3 

    The article discusses the effectiveness of AloeCure for the treatment of acid reflux.

  • Proton Pump Inhibitor Should Be Initial Drug Therapy to Control Reflux.  // Modern Medicine;Oct98, Vol. 66 Issue 10, p11 

    Discusses the abstract of the article `Consensus statement for management of gastroesophageal reflux disease: Result of a workshop meeting at Yale University School of Medicine, November 16 and 17, 1997,' by S.F. Moss, Arnold R. Tytgat GNJ et al, published in the July 1998 issue of the `Journal...

  • Effect of nifedipine administration (10 mg) on esophageal acid exposure time. Ishikawa, Hisagi; Iwakiri, Katsuhiko; Sugiura, Toshiaki; Kobayashi, Masafumi // Journal of Gastroenterology;2000, Vol. 35 Issue 1, p43 

    Abstract: The effect of nifedipine administration (10mg) on esophageal acid exposure time was investigated in 11 non-reflux esophagitis (non-RE) patients and 11 grade C (Los Angeles classification) reflux esophagitis (RE) patients. In each subject, esophageal pH monitoring was performed, with...

  • MedSurg Minute.  // MEDSURG Nursing;Aug99, Vol. 8 Issue 4, p256 

    Presents the steps in the management of gastroesophageal reflux disease, according to the International Foundation for Functional Gastrointestinal Disorders.

  • Managing complicated GERD. Castell, Donald O.; Pennachio, Dorothy L. // Patient Care;8/30/2001, Vol. 35 Issue 16, p1 

    Focuses on the management of patients with gastroesophageal reflux disease (GERD). Manifestations of the disease; Advances in diagnosis and therapy; Description of a typical case of complicated GERD; Treatment for the disease; Role of ablation in treating patients with Barrett's esophagus.

  • Use of acid reduction therapy and medical costs among medically versus surgically managed GERD patients: 30-month updated results. Sullivan, Erin M; Pelletier, Elise M; Richter, Joel E // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS236 

    An abstract of the article "Use of Acid Reduction Therapy and Medical Costs Among Medically Versus Surgically Managed GERD Patients: 30-month Updated Results," by Erin M. Sullivan, Elise M. Pelletier, and Joel E. Richter is presented.

  • GASTROESOPHAGEAL REFLUX DISEASE.THERAPEUTICAL OPTIONS. Munteanu, A. C.; Drăguşin, L.; Şurlin, V.; Munteanu, M.; Vasile, L.; Pogoran, Nicoleta; Pîrşcoveanu, M.; Ruxanda, Anca; Iordache, Violeta // Current Health Sciences Journal;2015, Vol. 41 Issue 1, p80 

    An abstract of the article "Gastroesophageal Reflux Disease. Therapeutical Options," by A.C. Munteanu and colleagues is presented.

  • Gastroesophageal Reflux Disease: Diagnosis and Management. Scott, Mark; GELHOT, AIMEE R. // American Family Physician;3/1/1999, Vol. 59 Issue 5, p1161 

    Part I. Discusses the etiology and treatment of gastroesophageal reflux disease. Overview of the disease; Pathophysiology; Clinical presentation; Response to omeprazole.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics